- In November 2022, The TruClear system, a mechanically operated hysteroscopic tissue removal tool for the safe and efficient treatment of intrauterine abnormalities (IUA), was recently introduced by India Medtronic Private Limited. IUA is frequently used to diagnose conditions, including fibroids, polyps, adhesions, cancers, hyperplasia, and retained products of conception.
- In November 2023, to increase the commercialization of its sonata treatment, which targets uterine fibroids, Gynesonics announced an investment of $67 million.
- In June 2022, The Healthcare Products Regulatory Agency (MHRA) and UK Medicines have authorized the marketing of Yselty, an oral GnRH antagonist, to treat mild to severe signs and symptoms of uterine fibroids (UF) in adult women of reproductive years. ObsEva SA is a biopharmaceutical company developing and commercializing novel health therapies for women
